PFE Jul 2024 31.000 call
| Previous close | 0.0600 |
| Open | 0.0900 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 31.00 |
| Expiry date | 2024-07-26 |
| Day's range | 0.0600 - 0.0900 |
| Contract range | N/A |
| Volume | |
| Open interest | 157 |
BloombergAlnylam Shares Soar After Drug Meets Goal in Heart Disease Trial
(Bloomberg) -- Alnylam Pharmaceuticals Inc. shares soared after its drug succeeded in treating a progressive and deadly form of heart disease, potentially opening up a new avenue for the company’s top-selling product. Most Read from BloombergHow Long Can High Rates Last? Bond Markets Say Maybe ForeverNvidia Sales Grow So Fast That Wall Street Can’t Keep UpJain Raises $5.3 Billion in Biggest Hedge Fund Debut Since 2018Russia Is Storing Up a Crime Wave When Its War on Ukraine EndsYen Is Under Pres
Insider MonkeyThe Most Populated Country in the World
We recently compiled a list of the 50 Most Populated Countries in the World and in this article, we will look at the most populated country in the world as of 2024. Trends in Population Growth Across the Globe According to data from the United Nations, the global population has increased three fold as compared […]
Investor's Business DailySarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy
Sarepta stock rocketed Friday after hitting a "grand slam" approval that expands the market for its Duchenne muscular dystrophy gene therapy more than tenfold, according to one estimate.
